Want to see TSE:BLAB full AI Analyst Report?
Total Valuation
Britannia Life Sciences Inc has a market cap or net worth of C$11.36M. The enterprise value is >-C$0.01.
Market CapC$11.36M
Enterprise Value>-C$0.01
Share Statistics
Britannia Life Sciences Inc has 162,254,330 shares outstanding. The number of shares has decreased by -2.65% in one year.
Shares Outstanding162,254,330
Owned by Insiders―
Owned by Institutions―
Financial Efficiency
Britannia Life Sciences Inc’s return on equity (ROE) is 0.63 and return on invested capital (ROIC) is -6.62%.
Return on Equity (ROE)0.63
Return on Assets (ROA)0.55
Return on Invested Capital (ROIC)-6.62%
Return on Capital Employed (ROCE)-0.07
Revenue Per Employee16.96K
Profits Per Employee466.93K
Employee Count28
Asset Turnover0.02
Inventory Turnover0.00
Valuation Ratios
The current PE Ratio of Britannia Life Sciences Inc is 0.9. Britannia Life Sciences Inc’s PEG ratio is -0.00294.
PE Ratio0.9
PS Ratio30.75
PB Ratio0.70
Price to Fair Value0.70
Price to FCF-12.63
Price to Operating Cash Flow-17.14
PEG Ratio-0.00294
Income Statement
In the last 12 months, Britannia Life Sciences Inc had revenue of 474.83K and earned 13.07M in profits. Earnings per share was 0.08.
Revenue474.83K
Gross Profit38.86K
Operating Income-1.46M
Pretax Income13.58M
Net Income13.07M
EBITDA-1.39M
Earnings Per Share (EPS)0.08
Cash Flow
In the last 12 months, operating cash flow was -1.16M and capital expenditures 7.00, giving a free cash flow of -1.16M billion.
Operating Cash Flow-1.16M
Free Cash Flow-1.16M
Free Cash Flow per Share>-0.01
Dividends & Yields
Britannia Life Sciences Inc pays an annual dividend of ―, resulting in a dividend yield of ―
Dividend Per Share―
Dividend Yield―
Payout RatioN/A
Free Cash Flow Yield―
Earnings Yield―
Stock Price Statistics
Beta-1.21
52-Week Price Change0.00%
50-Day Moving Average0.07
200-Day Moving Average0.09
Relative Strength Index (RSI)55.31
Average Volume (3m)73.07K
Important Dates
Britannia Life Sciences Inc upcoming earnings date is Nov 26, 2026, After Close (Confirmed).
Last Earnings DateAug 27, 2026
Next Earnings DateNov 26, 2026
Ex-Dividend Date―
Financial Position
Britannia Life Sciences Inc as a current ratio of 6.57, with Debt / Equity ratio of 0.96%
Current Ratio6.57
Quick Ratio6.57
Debt to Market Cap<0.01
Net Debt to EBITDA0.79
Interest Coverage Ratio-57.36
Taxes
In the past 12 months, Britannia Life Sciences Inc has paid 507.84K in taxes.
Income Tax507.84K
Effective Tax Rate0.04
Enterprise Valuation
Britannia Life Sciences Inc EV to EBITDA ratio is -9.69, with an EV/FCF ratio of -11.68.
EV to Sales28.44
EV to EBITDA-9.69
EV to Free Cash Flow-11.68
EV to Operating Cash Flow-11.68
Balance Sheet
Britannia Life Sciences Inc has C$17.14M in cash and marketable securities with C$229.14K in debt, giving a net cash position of C$16.91M billion.
Cash & Marketable SecuritiesC$17.14M
Total DebtC$229.14K
Net CashC$16.91M
Net Cash Per ShareC$0.10
Tangible Book Value Per ShareC$0.13
Margins
Gross margin is 7.38%, with operating margin of -306.82%, and net profit margin of 2753.40%.
Gross Margin7.38%
Operating Margin-306.82%
Pretax Margin2860.35%
Net Profit Margin2753.40%
EBITDA Margin-293.59%
EBIT Margin-306.82%
Analyst Forecast
The average price target for Britannia Life Sciences Inc is ―, which is 11.43% higher than the current price. The consensus rating is ―
Price Target―
Price Target Upside―
Analyst Consensus―
Analyst Count0
Revenue Growth Forecast―
EPS Growth Forecast―